The Dual Inhibition of SYK & JAK Kinases for the Treatment of Skin & Complex Inflammatory Conditions
Time: 11:40 am
day: Day Two
- Addressing novel treatments in Chronic Hand Eczema as therapy gusacitinib, a dual SYK/JAK inhibitor, advances to phase 3 clinical development.
- Evaluating additional role of TYK2 and SYK in epithelial cell/keratinocyte function
- Detailing further potential in dermatologic and immunologic condition